205 views
Real help for those affected or media hype - what can we really expect from the new drugs for treating Alzheimer's disease? Experts around the world are holding controversial discussions about the so-called monoclonal antibodies, which are intended for the treatment of mild cognitive impairment and Alzheimer's dementia. The webinar will use the facts from research to answer the most important questions on the topic, including the following: • How effective are the new drugs? • What side effects are there? • Is this a treatment that targets one of the causes of Alzheimer's disease? • Are there other therapeutic approaches that are worth researching in the future? • What proven measures can be used to prevent Alzheimer's dementia? The doctor and health care researcher Prof. Dr. med. Elmar Gräßel is the head of the Center for Medical Health Care Research at the University Hospital Erlangen and one of the project leaders of digiDEM Bavaria. He has been researching the topic of "dementia" for 35 years and is a founding member of the German Alzheimer Society.